- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04818996
Evaluation of the Effect of Mediterranean Diet on Breast Cancer Patients
Evaluation of the Effect of Mediterranean Diet on Body Composition, Oxidant Stress and Proinflammatory Markers in Breast Cancer Patients
Study Overview
Detailed Description
Breast cancer is the most common type of cancer among women in both developed and developing countries and is the leading cause of cancer death among women worldwide. Breast cancer is a disease that can develop and progress for various reasons. In addition to unchangeable factors such as increasing age and genotype, modifiable factors such as smoking, alcohol consumption, lack of physical activity, malnutrition, and obesity play a role in the pathogenesis of the disease.
Breast cancer risk increases with increasing body mass index (BMI) in postmenopausal women. Chronic inflammation in obesity is associated with an increase in the release of proinflammatory factors (such as TNF-α, IL-1, IL-6). This situation; It is a risk factor for many types of cancer such as colon, stomach, breast and prostate carcinomas and supports a cause-effect relationship between obesity and cancer. These proinflammatory factors act as signal converters for tumor growth and progression. Obese women have elevated levels of TNF-α and IL-6 in the circulation, and this is associated with the development and progression of breast tumors.
The Mediterranean Diet, which consists of high amounts of monounsaturated fatty acids, fruits, vegetables and whole grains, has been widely evaluated and indicated as an important factor in preventing tumor formation from inflammatory pathways.
Weight loss improves the antitumor immune system, lowers estrogen levels, reduces the risk of breast cancer and has been associated with better outcomes in obese patients. Lifestyle intervention studies strongly suggest that weight loss is possible and observational studies can actually improve breast cancer survival.In this regard, a healthy lifestyle and diet are the first steps to prevent breast cancer.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Efeler
-
Aydın, Efeler, Turkey, 09100
- Aydın Adnan Menderes University, Faculty of Health Sciences, Department of Nutrition and Dietetics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 18 years old,
- BMI value to be ≥25 kg/m2,
- To be diagnosed with breast cancer stage I, II or III,
- Being a positive hormone receptor status, one of the biological subtypes of breast cancer,
- Having completed chemotherapy and / or radiotherapy treatment at least 6 months before starting the study,
- Not applying any treatment for body weight loss,
- Accepting to participate in the study,
- Perceiving disorder and not having communication problems.
Exclusion Criteria:
- Being under the age of 18 and over the age of 65,
- BMI value to be 40 kg/m2,
- Having advanced stage breast cancer (IV and V),
- Being diagnosed with cancer or metastasis in other organs,
- Being one of the biological subtypes of breast cancer, hormone receptor status being negative,
- Using antioxidant vitamin-mineral supplements,
- Using herbal supplements,
- Being pregnant or planning a pregnancy,
- To stop working after starting diet therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Mediterranean Diet
In the study, the participants were applied a diet compatible with the Mediterranean diet for 8 weeks.
|
While calculating the energy of the Mediterranean diet applied to the individuals participating in the study, Mifflin-St. Jeor equation is used. The macronutrient composition of the Mediterranean diet was calculated as 36-40% fat, 40-45% carbohydrate and 15-20% protein. This diet is enriched with natural foods (fruits, vegetables, legumes, whole grain foods, fish, olive oil and oilseeds such as walnuts and almonds). In addition, anthropometric measurements and body composition analysis of the participants were performed both at the beginning and at the end of the study, and some biochemical parameters (IL-6, TNF-α, CRP, MDA, TAS, TOS and routine blood parameters) were evaluated. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in body weight
Time Frame: Baseline, 8 weeks
|
Body weight (kg) was measured using the InBody 270 brand device.
|
Baseline, 8 weeks
|
|
Change in body mass indexs
Time Frame: Baseline, 8 weeks
|
The BMI is defined as the body mass divided by the square of the body height, and is expressed in units of kg/m^2, resulting from mass in kilograms and height in metres.
|
Baseline, 8 weeks
|
|
Change in fat mass measured by bioelectrical impedance analyzer
Time Frame: Baseline, 8 weeks
|
Fat mass (kg) was measured using the InBody 270 brand device.
|
Baseline, 8 weeks
|
|
Change in fat-free mass measured by bioelectrical impedance analyzer
Time Frame: Baseline, 8 weeks
|
Fat-free mass (kg) was measured using the InBody 270 brand device.
|
Baseline, 8 weeks
|
|
Change in resting metabolic rate (RMR) measured by bioelectrical impedance analyzer
Time Frame: Baseline, 8 weeks
|
RMR (kcal) was measured using the InBody 270 brand device.
|
Baseline, 8 weeks
|
|
Change in interleukin 6 (IL-6)
Time Frame: Baseline, 8 weeks
|
Blood was drawn from participants for assessment of IL-6 (pg/mL) at the beginning and end of the study after fasting for at least 8 hours
|
Baseline, 8 weeks
|
|
Change in tumor necrosis factor alpha (TNF-α)
Time Frame: Baseline, 8 weeks
|
Blood was drawn from participants for assessment of TNF-α (pg/mL) at the beginning and end of the study after fasting for at least 8 hours
|
Baseline, 8 weeks
|
|
Change in malondialdehyde (MDA)
Time Frame: Baseline, 8 weeks
|
Blood was drawn from participants for assessment of MDA (mmol/L) at the beginning and end of the study after fasting for at least 8 hours
|
Baseline, 8 weeks
|
|
Change in total antioxidant status (TAS)
Time Frame: Baseline, 8 weeks
|
Blood was drawn from participants for assessment of TAS (mmol/L) at the beginning and end of the study after fasting for at least 8 hours
|
Baseline, 8 weeks
|
|
Change in total oxidant status (TOS)
Time Frame: Baseline, 8 weeks
|
Blood was drawn from participants for assessment of TOS (µmol/L) at the beginning and end of the study after fasting for at least 8 hours
|
Baseline, 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in waist circumference
Time Frame: Baseline, 8 weeks
|
Waist circumference (cm) was measured with a non-stretch tape measure.
|
Baseline, 8 weeks
|
|
Change in hip circumference
Time Frame: Baseline, 8 weeks
|
Hip circumference (cm) was measured with a non-stretch tape measure.
|
Baseline, 8 weeks
|
|
Change in dietary inflammatory index (DII)
Time Frame: Baseline, 8 weeks
|
Dietary inflammatory index (DII) was calculated with 3-day food consumption record.
|
Baseline, 8 weeks
|
|
Change in oxidative stress index (OSI)
Time Frame: Baseline, 8 weeks
|
The oxidative stress index (OSI) value expressed as a percentage of the ratio of serum total oxidant status (TOS) levels to total antioxidant status (TAS) levels was calculated.
|
Baseline, 8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Burcu Deniz Güneş, Aydın Adnan Menderes University, Faculty of Health Sciences, Department of Nutrition and Dietetics
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019/044
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Mediterranean Diet
-
Purdue UniversityMushroom CouncilCompleted
-
Miguel López MorenoIMDEA Food; Hospital Clinico Universitario San Cecilio; Hospital Universitario...Not yet recruitingMetabolic Dysfunction-associated Liver DiseaseSpain
-
Coordinación de Investigación en Salud, MexicoEnrolling by invitationObstructive Sleep ApneaMexico
-
Penn State UniversityAlliance for Potato Research & EducationNot yet recruitingPrediabetes
-
Erasmus Medical CenterRecruitingAcromegaly Due to Pituitary Adenoma | Mediterranean Diet | Ketogenic DietNetherlands
-
University of East AngliaNewcastle UniversityCompletedDepression, AnxietyUnited Kingdom
-
University of California, IrvineCompletedPolycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myeloproliferative Disorder | Myeloproliferative SyndromeUnited States
-
Firat UniversityThe Scientific and Technological Research Council of TurkeyCompletedMediterranean Diet | Multiple Sclerosis (MS) - Relapsing-remittingTurkey (Türkiye)
-
Azienda Ospedaliera Specializzata in Gastroenterologia...Completed
-
Parc de Salut MarRecruitingHIV Infection | Inflammation | Cardiovascular Risk | Mediterranean DietSpain